In melanoma mice, HP-APS treatment reduced the size of tumors, increased the proportion of CD8+ T cells, and resulted in a slower rate of tumor growth when combined with PD-1 monoclonal antibody (PD-1 mAb) treatment, indicating a possible synergistic effect. The gene discussed is CD8A; the disease is neoplasm.